Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol

Study Overview
=================
Brief Summary
-----------------
To research the effect of propranolol on the proliferation and apoptosis of gastrointestinal cancer.

Official Title
-----------------
Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol

Conditions
-----------------
Gastrointestinal Cancer

Intervention / Treatment
-----------------
* Drug: Propranolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with gastric adenocarcinoma and colon cancer were diagnosed by histology and cytology, and there was a clear metastasis (TxNxM0); without any prior treatment (including surgery or radiotherapy and chemotherapy) in the I-III period, no distant metastasis, suitable for patients with surgical resection of the tumor. the age range of the patients is 18-60; systolic pressure 100-140mmHg; heart rate >60bpm; the patient's survival time should be longer than 3 months; without previous cardiovascular and cerebrovascular diseases, the atrioventricular block was excluded by the 24 hour dynamic electrocardiogram; ECOG score of 2 (that means the patient's bed time is less than 50%); Karnofsky score of 60% (that means patients have the basic activities and self-care ability); the basic biochemical examination results of patients with normal: white blood cell 3000/ul; neutrophil 1500/ul 100000/ul; platelet count; total bilirubin < 1.5 x ULN; AST / ALT 2.5 x ULN without liver metastasis; < 5 x ULN liver metastasis; creatinine clearance rate of 1.5 x ULN; have the ability to understand and sign informed consent. Exclusion Criteria: pregnant or lactating women; patients with severe heart disease, kidney disease, metabolic disorders, bronchial asthma, cardiogenic shock, heart block (II-III degree atrioventricular block), or severe acute heart failure, sinus bradycardia. patients with epilepsy or psychotropic drugs and sedatives; patients with brain metastasis and bone marrow metastasis; participants in clinical trials of other drugs within 4 weeks; patients with a history of anaphylaxis with propranolol; patients treated with trastuzumab; patients with or reactive immunodeficiency, such as those with HIV infection; the uncontrollable situation in the group during the period (but not limited to these cases): according to the experimental scheme of medication, severe infection, due to mental illness or other social factors lead to the compliance requirements of patients; patients with atrioventricular block should be discontinued immediately and quit; the researchers believe there may be any increase in the risk of the subject or any interference with clinical trials.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: placebo and propranolol<br>We used propranolol and placebo as an control drug to treat with patients. | Drug: Propranolol<br>* 0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.<br>* Other names: placebo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor size will be measured. | We used CT and Ki67 to confirm that the drug's affection. | Our experiment completed after patients took medicine for one week. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastrointestinal Cancer, Propranolol